Keyword: Iclusig

The SEC has charged two former Ariad employees and a spouse of a former employee with insider trading.

Takeda’s cancer unit debuted a new face at this year’s ASCO—and the company was quick to bill it as such.

Takeda is letting go of 180 of the nearly 300 employees picked up in its $5.2 billion buyout of Ariad but says some of those may still land jobs in its global operations.

In this week's FiercePharmaAsia wrap-up, Takeda has offered $5.2 billion to buy Ariad and made a $125 deal with Maverick on T-cell therapy R&D, Valeant sold Dendreon to a Chinese company for $820 million, and more.

Takeda plans to shell out $5.2 billion for the kind of deal most major drugmakers want: Ariad, its leukemia drug Iclusig and a pipeline with near-term prospects—and it's paying a pretty penny.

Incyte may have shelled out to license Ariad Pharmaceuticals’ leukemia therapy Iclusig in Europe, but the drug isn’t the crux of the deal. Incyte, revving up its pipeline of drug candidates, also wants to get its hands on Ariad’s commercial infrastructure on the continent.